What it's for (Indications)
- This combination therapeutic agent, typically comprising elemental calcium (e.
- g.
- , from calcium carbonate or citrate), cholecalciferol (Vitamin D3) or ergocalciferol (Vitamin D2), and menaquinone (Vitamin K2, e.
- g.
- , MK-4 or MK-7), is primarily indicated for the prevention and treatment of calcium and vitamin D deficiencies.
- Its principal use lies in supporting bone health, particularly in populations at risk of osteoporosis, such as postmenopausal women, elderly individuals, and those with inadequate dietary intake or malabsorption syndromes.
- It aids in maintaining skeletal integrity, reducing fracture risk, and promoting optimal bone mineralization.
- Furthermore, it may be used as an adjunct in the management of specific conditions requiring increased calcium and vitamin D supplementation, under medical supervision.
- The inclusion of Vitamin K2 aims to enhance calcium utilization within bone tissue while potentially mitigating soft tissue calcification.
- This comprehensive approach addresses multifaceted aspects of calcium metabolism, crucial for long-term musculoskeletal and overall health.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for calcium, vitamin D, and vitamin K2 supplements are highly individualized and must be determined by a healthcare professional based on the patient's age, sex, existing nutritional status, underlying medical conditions, and specific therapeutic goals. Typical daily recommendations for elemental calcium often range from 500 mg to 1200 mg, usually divided into two or three doses for optimal absorption. Vitamin D supplementation commonly ranges from 600 IU to 2000 IU (15 mcg to 50 mcg) daily, though higher doses may be prescribed for deficiency correction. Vitamin K2 dosages, particularly for menaquinone-7 (MK-7), frequently range from 45 mcg to 180 mcg per day. It is crucial to consider total dietary intake of these nutrients and monitor serum calcium, 25-hydroxyvitamin D levels, and other relevant biochemical markers regularly to prevent over-supplementation and ensure efficacy. Adherence to prescribed dosages and periodic re-evaluation are paramount for safety and effectiveness. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated when administered within recommended dosages, the combination of calcium, vitamin D, and vitamin K2 can elicit various side effects.
- Common gastrointestinal adverse effects associated with calcium supplementation include constipation, bloating, abdominal discomfort, flatulence, and nausea.
- These symptoms are often dose-dependent and may be alleviated by adjusting the form of calcium or dosage.
- Higher doses of vitamin D, particularly when combined with high calcium intake, can lead to hypercalcemia (elevated serum calcium levels), which may manifest as polyuria, polydipsia, weakness, fatigue, headache, appetite loss, and, in severe cases, cardiac arrhythmias or renal impairment.
- Hypercalciuria (excessive calcium in urine) increases the risk of nephrolithiasis (kidney stone formation).
- Less common side effects may include allergic reactions (e.
- g.
- , rash, itching), though these are rare.
- Patients should report any persistent or severe adverse reactions, especially those indicative of hypercalcemia, to their healthcare provider for evaluation and appropriate management.
Serious Warnings
- Black Box Warning: No formal FDA Black Box Warning is typically assigned to oral calcium, vitamin D, and vitamin K2 supplements. However, serious warnings and precautions are paramount. The principal serious risks associated with this combination involve the potential for hypercalcemia and hypercalciuria, especially in susceptible individuals or with excessive dosing. Uncontrolled hypercalcemia can lead to severe and potentially irreversible organ damage, including nephrocalcinosis, renal failure, cardiac arrhythmias, and vascular calcification. Patients with pre-existing conditions such as renal impairment, a history of kidney stones, hyperparathyroidism, or granulomatous diseases (e.g., sarcoidosis) are at significantly elevated risk and require meticulous clinical assessment and vigilant monitoring of serum calcium, urinary calcium excretion, and 25-hydroxyvitamin D levels. Concomitant use with medications known to affect calcium metabolism, such as thiazide diuretics or digoxin, necessitates extreme caution and dose adjustment under medical supervision. Any symptoms suggestive of hypercalcemia (e.g., nausea, vomiting, constipation, polyuria, polydipsia, muscle weakness, confusion) warrant immediate discontinuation of the supplement and urgent medical evaluation.
- Although a formal FDA Black Box Warning is not typically assigned to calcium, vitamin D, and vitamin K2 supplements, significant precautions and serious warnings must be considered prior to and during therapy.
- Patients with a history of hypercalcemia, hypercalciuria, or calcium-containing kidney stones are at increased risk of exacerbation and should be closely monitored or, in some cases, these supplements may be contraindicated.
- Individuals with severe renal impairment or end-stage renal disease require careful dose adjustment and monitoring of calcium and phosphate levels due to impaired excretion and increased risk of vascular calcification.
- Caution is advised in patients with sarcoidosis, hyperparathyroidism, or other granulomatous diseases, as these conditions can lead to increased vitamin D sensitivity and hypercalcemia.
- Concomitant use with certain medications, such as thiazide diuretics (risk of hypercalcemia), digoxin (risk of arrhythmias with hypercalcemia), corticosteroids (decrease calcium absorption), or certain antibiotics (e.
- g.
- , tetracyclines, fluoroquinolones, reduced absorption), necessitates careful medical supervision due to potential drug interactions affecting calcium metabolism or increasing toxicity risk.
- Regular monitoring of serum calcium, 25-hydroxyvitamin D, and renal function is imperative to prevent adverse events, especially in vulnerable populations.
- Any symptoms indicative of hypercalcemia should prompt immediate medical evaluation.
How it Works (Mechanism of Action)
The therapeutic efficacy of this combination product stems from the synergistic actions of its components in regulating calcium homeostasis and bone metabolism. Calcium, an essential mineral, serves as the primary structural component of bone and teeth, and is crucial for numerous physiological processes, including nerve impulse transmission, muscle contraction, and blood coagulation. Vitamin D (cholecalciferol/ergocalciferol) acts as a prohormone, which, after hepatic and renal hydroxylation to its active form, calcitriol (1,25-dihydroxyvitamin D), significantly enhances the intestinal absorption of dietary calcium and phosphate. This process is vital for maintaining adequate serum calcium and phosphate levels, which are necessary for proper bone mineralization and preventing hypocalcemia. Vitamin K2 (menaquinone) plays a pivotal role in activating specific vitamin K-dependent proteins, notably osteocalcin and matrix Gla protein (MGP). Activated osteocalcin, produced by osteoblasts, facilitates the incorporation of calcium into the bone matrix, promoting proper bone mineralization and strength. Concurrently, activated MGP inhibits the deposition of calcium in soft tissues, such as arterial walls, thereby supporting cardiovascular health by preventing vascular calcification. This tripartite mechanism ensures efficient calcium utilization, promotes bone integrity, and potentially mitigates risks associated with calcium maldistribution and cardiovascular calcification.
Commercial Brands (Alternatives)
No other brands found for this formula.